Alterity Therapeutics Ltd FDA Minutes Confirm Single Trial Path for ATH434 in MSA
FDA minutes confirm registrational path for Alterity’s ATH434 in MSA
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received the official written End-of-Phase 2 (EOP2) meeting minutes from the U.S. Food and Drug Administration (FDA) for its lead candidate ATH434 in Multiple System Atrophy (MSA).
Announced on 7 July 2026, the minutes confirm the key outcomes previously reported on 9 June 2026 and add fresh detail on the planned Phase 3 protocol. Critically, the FDA agreed that a single pivotal trial plus confirmatory evidence could support approval of ATH434, offering an efficient route toward a potential New Drug Application (NDA) filing.
The Company noted that Phase 3 trial activities remain on track to initiate by year-end 2026. For investors, the written minutes help de-risk the regulatory pathway for a lead asset targeting a disease with no approved treatments that slow progression.
When big ASX news breaks, our subscribers know first
What the FDA minutes confirmed
The EOP2 minutes confirmed that the FDA agreed with the proposed Phase 3 trial design, including the study population, treatment regimen, and efficacy endpoints. This written alignment provides regulatory validation of the development strategy Alterity outlined in June.
Agreement was reached on the selection and analysis of the primary endpoint, alongside a set of key secondary measures assessing symptoms that affect daily life for people living with MSA.
- Primary endpoint: 11-item UMSARS Part I rating scale, a functional measure of activities of daily living
- Secondary: Swallowing Disturbance Questionnaire (SDQ)
- Secondary: Orthostatic Hypotension Symptom Assessment (OHSA)
- Secondary: Clinical Global Impression of Severity (CGI-S)
The FDA further indicated that a single pivotal trial plus confirmatory evidence could provide the necessary data to support approval. Alterity expects that data from its ATH434-201 Phase 2 clinical trial will provide the required confirmatory evidence.
MuSyCA composite scale results from the completed Phase 2 programme showed a 41% relative treatment effect versus placebo at Week 52, corroborated by a separate MMRM analysis on modified UMSARS Part I that reached a 53% relative treatment effect, reinforcing the clinical foundation on which the Phase 3 design rests.
The regulator also indicated that the anticipated size of Alterity’s safety database at the conclusion of the Phase 3 was “reasonable,” an important signal ahead of a registrational programme.
Phase 3 trial design at a glance
| Parameter | Detail |
|---|---|
| Patients enrolled | Approximately 200 |
| Randomisation | 1:1 ratio |
| Treatment | ATH434 50 mg vs matching placebo, twice daily |
| Duration | 12 months |
| Open-label extension | Offered to trial completers (enhances safety database) |
David Stamler, M.D., Chief Executive Officer
“The official meeting minutes confirm the alignment we reached with the FDA and provide a well-defined clinical development strategy for registration. The FDA’s willingness to accept a single pivotal trial supported by confirmatory evidence reflects a clear pathway for ATH434 in MSA. With the Phase 3 design elements confirmed, we are finalizing the protocol and remain on track to initiate Phase 3 trial activities by year-end 2026.”
Why a single pivotal trial matters for investors
The FDA’s acceptance of a single pivotal trial plus confirmatory evidence offers an efficient route to completion of the clinical development programme, both in time and resources required.
For investors, a reduced trial burden lowers the cost and shortens the timeline toward a potential commercial product. It also builds on existing regulatory advantages for the candidate.
ATH434 has been granted Fast Track Designation by the FDA. It has also received Orphan Drug Designation from both the FDA and the European Commission for the treatment of MSA.
Dr. Daniel Claassen, MD, Chief Medical Advisor
“The Phase 2 results for ATH434 were among the most encouraging I have seen in the field, and the alignment reached with the FDA on the Phase 3 trial design is an important next step in bringing a meaningful new treatment option to people living with this devastating disease.”
Understanding MSA and how ATH434 works
Multiple System Atrophy is a rare, rapidly progressive neurodegenerative disease characterised by failure of the autonomic nervous system and impaired movement. It is a Parkinsonian disorder, meaning it shares features such as slowed movement and rigidity, alongside autonomic dysfunction affecting involuntary functions like blood pressure and bladder control.
A pathological hallmark of MSA is the abnormal clumping of the protein α-synuclein within oligodendrocytes, the support cells that produce the protective coating around nerve fibres in the central nervous system.
MSA affects up to 50,000 individuals in the U.S. While some symptoms can be managed with medication, there are currently no drugs able to slow disease progression, and no cure exists.
ATH434 is an oral iron chaperone designed to reduce iron accumulation and inhibit abnormal protein aggregation associated with neurodegeneration. In preclinical models, it has been shown to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain.
For readers interested in the scientific underpinning of ATH434’s mechanism, our deep-dive into ATH434’s QSM biomarker validation covers the peer-reviewed NeuroImage study confirming that quantitative susceptibility mapping can detect disease-specific iron accumulation and distinguish MSA from Parkinson’s disease, providing the objective measurement framework that supports ATH434’s treatment response tracking in Phase 3.
The next major ASX story will hit our subscribers first
What’s next for Alterity
With the Phase 3 design elements now confirmed in writing, the Company is finalising the Phase 3 protocol. Phase 3 trial activities remain on track to initiate by year-end 2026.
The programme is intended to lead toward a potential New Drug Application (NDA) filing, supported by confirmatory evidence from the ATH434-201 Phase 2 trial. Alterity also plans to offer an open-label extension to participants who complete the Phase 3 trial, both to continue their treatment and to enhance the safety database for ATH434.
The written minutes provide added clarity on the regulatory pathway, giving investors a defined roadmap ahead of the planned Phase 3 initiation.
Don’t Miss the Next Biotech Breakthrough on the ASX
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market on biotech and health sector developments. Click the “Free Alerts” button at Big News Blast to receive the moment-it-drops coverage that keeps you ahead of the market.